In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject

被引：92

作者：

Tsibris, Athe M. N. ^{[1
,2
]}

Sagar, Manish ^{[2
,3
]}

Gulick, Roy M. ^{[4
]}

Su, Zhaohui ^{[5
]}

Hughes, Michael ^{[5
]}

Greaves, Wayne ^{[6
]}

Subramanian, Mani

Flexner, Charles ^{[7
]}

Giguel, Francoise ^{[1
]}

Leopold, Kay E. ^{[8
]}

Coakley, Eoin ^{[9
]}

Kuritzkes, Daniel R. ^{[2
,3
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Brigham & Womens Hosp, Boston, MA 02115 USA

[4] Cornell Univ, Weill Med Coll, New York, NY 10021 USA

[5] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[6] Schering Plough Res Inst, Kenilworth, NJ USA

[7] Johns Hopkins Univ, Baltimore, MD USA

[8] Harvard Univ, Cambridge, MA 02138 USA

[9] Monogram Biosci, San Francisco, CA USA

来源：

JOURNAL OF VIROLOGY | 2008年 / 82卷 / 16期

关键词：

D O I：

10.1128/JVI.00444-08

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Little is known about the in vivo development of resistance to human immunodeficiency virus type 1 (HIV-1) CCR5 antagonists. We studied 29 subjects with virologic failure from a phase IIb study of the CCR5 antagonist vicriviroc (VCV) and identified one individual with HIV-1 subtype C who developed VCV resistance. Studies with chimeric envelopes demonstrated that changes within the V3 loop were sufficient to confer VCV resistance. Resistant virus showed VCV-enhanced replication, cross-resistance to another CCR5 antagonist, TAK779, and increased sensitivity to aminooxypentane-RANTES and the CCR5 monoclonal antibody HGS004. Pretreatment V3 loop sequences reemerged following VCV discontinuation, implying that VCV resistance has associated fitness costs.

引用

页码：8210 / 8214

页数：5

共 23 条

[1] Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss
Anastassopoulou, Cleo G.
Marozsan, Andre J.
Matet, Alexandre
Snyder, Amy D.
Arts, Eric J.
Kuhmann, Shawn E.
Moore, John P.
[J]. PLOS PATHOGENS, 2007, 3 (06) : 720 - 732
[2] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M
Nishimura, O
Kanzaki, N
Okamoto, M
Sawada, H
Iizawa, Y
Shiraishi, M
Aramaki, Y
Okonogi, K
Ogawa, Y
Meguro, K
Fujino, M
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) : 5698 - 5703
[3] Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Gulick, Roy M.
Su, Zhaohui
Flexner, Charles
Hughes, Michael D.
Skolnik, Paul R.
Wilkin, Timothy J.
Gross, Robert
Krambrink, Amy
Coakley, Eoin
Greaves, Wayne L.
Zolopa, Andrew
Reichman, Richard
Godfrey, Catherine
Hirsch, Martin
Kuritzkes, Daniel R.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (02) : 304 - 312
[4] DETECTION OF REPLICATION-COMPETENT AND PSEUDOTYPED HUMAN-IMMUNODEFICIENCY-VIRUS WITH A SENSITIVE CELL-LINE ON THE BASIS OF ACTIVATION OF AN INTEGRATED BETA-GALACTOSIDASE GENE
KIMPTON, J
EMERMAN, M
[J]. JOURNAL OF VIROLOGY, 1992, 66 (04) : 2232 - 2239
[5] Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
Kuhmann, SE
Pugach, P
Kunstman, KJ
Taylor, J
Stanfield, RL
Snyder, A
Strizki, JM
Riley, J
Baroudy, BM
Wilson, IA
Korber, BT
Wolinsky, SM
Moore, JP
[J]. JOURNAL OF VIROLOGY, 2004, 78 (06) : 2790 - 2807
[6] Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients
Lalezari, Jacob
Yadavalli, Gopal K.
Para, Michael
Richmond, Gary
DeJesus, Edwin
Brown, Stephen J.
Cai, Wendy
Chen, Cecil
Zhong, John
Novello, Lu Anne
Lederman, Michael M.
Subramanian, G. Mani
[J]. JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (05) : 721 - 727
[7] Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
Marozsan, AJ
Kuhmann, SE
Morgan, T
Herrera, C
Rivera-Troche, E
Xu, S
Baroudy, BM
Strizki, J
Moore, JP
[J]. VIROLOGY, 2005, 338 (01) : 182 - 199
[8] Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates
Marozsan, AJ
Arts, EJ
[J]. JOURNAL OF VIROLOGICAL METHODS, 2003, 111 (02) : 111 - 120
[9] HIV-1 TROPISM FOR MONONUCLEAR PHAGOCYTES CAN BE DETERMINED BY REGIONS OF GP120 OUTSIDE THE CD4-BINDING DOMAIN
OBRIEN, WA
KOYANAGI, Y
NAMAZIE, A
ZHAO, JQ
DIAGNE, A
IDLER, K
ZACK, JA
CHEN, ISY
[J]. NATURE, 1990, 348 (6296) : 69 - 73
[10] Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES
Pastore, C
Picchio, GR
Galimi, F
Fish, R
Hartley, O
Offord, RE
Mosier, DE
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) : 509 - 517

← 1 2 3 →